<DOC>
	<DOC>NCT00774267</DOC>
	<brief_summary>The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene or placebo. The primary endpoint in this study is the change in mammographic breast density between baseline and month 24 for each group.</brief_summary>
	<brief_title>Study Evaluating Changes In Mammographic Breast Density</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Subjects who have completed all scheduled evaluations in protocol 3115A1303WW. Completed 24 months of treatment in protocol 3115A1303. Had a mammogram at the baseline visit and at the month 24 visit in protocol 3115A1303, and both are original films that are technically acceptable for reading. Was at least 80% compliant with test article administration during protocol 3115A1303. Had a mammogram at either baseline or month 24 during the 3115A1303 study that was technically unsatisfactory. One or both mammograms were digitized when they were obtained during the 3115A1303 study. Had more than one mammogram at either the baseline or month 24 visit of study 3115A1303.</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>